^
1d
Neferine Ameliorates Psoriasis through Inducing Oxidative Stress-Mediated Keratinocyte Apoptosis and Suppressing Inflammatory Response via the Keap1-Nrf2 Pathway. (PubMed, Free Radic Biol Med)
A murine psoriasis model was induced by 6-day continuous topical imiquimod (IMQ) application; cellular models were established by stimulating keratinocyte lines with tumor necrosis factor-alpha (TNF-α)/interleukin-17A (IL-17A)...siNrf2 abolished Nef-mediated inhibition of NF-κB/ERK phosphorylation, cytokine down-regulation and ΔΨm loss. Neferine ameliorates psoriasis by inducing oxidative stress-driven apoptosis in hyper-proliferative keratinocytes and by activating Keap1-Nrf2-mediated anti-inflammatory signaling to block the IL-23/IL-17 axis, offering a promising small-molecule strategy for psoriasis management.
Journal
|
KEAP1 (Kelch Like ECH Associated Protein 1) • TNFA (Tumor Necrosis Factor-Alpha) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha)
|
Zyclara (imiquimod)
7d
Enzymatically-modified isoquercitrin alleviates skin inflammation, mast cell degranulation, and vascular hyperpermeability in a mouse model of plaque psoriasis. (PubMed, Int Immunopharmacol)
Therefore, this work aimed to evaluate the potential effect of enzymatically-modified isoquercitrin (EMIQ, 50 and 100 mg/kg body weight "b.wt", administered orally for 8 days), in comparison with methotrexate (MTX, a synthetic drug), against imiquimod (IMQ)-induced psoriatic lesions in female BALB/c mice. Moreover, oral administration of EMIQ prevented significantly (P < 0.001) the vascular permeability associated with augmented Evans blue leakage and dermal accumulation of degranulated mast cells, suggesting a reduction in inflammation and edema. Taken together, our study demonstrated that EMIQ can alleviate psoriasis and may be considered as a promising strategy for psoriasis treatment via targeting IL-23/IL-17A axis and mast cell degranulation.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • IL1B (Interleukin 1, beta)
|
methotrexate • Zyclara (imiquimod)
11d
Anti-Psoriatic Effects of J2H-1802, a Mycophenolate Mofetil and 5-Aminosalicylic Acid Hybrid, in an Imiquimod-Induced Psoriasis-like Mouse Model. (PubMed, Pharmaceutics)
In addition, J2H-1802 significantly reduced serum tumor necrosis factor-α (TNF-α) levels and suppressed pro-inflammatory cytokine expression, including IL-1β, IL-6, IL-17, and TNF-α, in psoriatic skin. J2H-1802 alleviates both local and systemic inflammatory features of psoriasis, suggesting its potential as a therapeutic candidate for targeting IL-23/Th17-mediated inflammatory pathways.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • IL1B (Interleukin 1, beta)
|
Zyclara (imiquimod)
11d
PTPN2 alleviates psoriasis by targeting the STING-STAT3 axis and restoring autophagy: in vitro and in vivo evidence. (PubMed, Immunobiology)
Using cellular and imiquimod-induced mouse models, we assessed PTPN2 expression and function using multiple techniques, including immunofluorescence, co-immunoprecipitation, and Western blotting...PTPN2 overexpression attenuated psoriatic pathology, and this therapeutic benefit was further enhanced by co-administering the autophagy inducer rapamycin. Collectively, our results delineate a novel mechanism by which PTPN2 alleviates psoriasis-like pathology in keratinocytes by targeting the STING-STAT3 pathway and promoting autophagy and apoptosis. These findings indicate that PTPN2 is a potential therapeutic target, with in vivo validation supporting its translational relevance.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • STING (stimulator of interferon response cGAMP interactor 1) • IL17A (Interleukin 17A) • PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2)
|
sirolimus • Zyclara (imiquimod)
11d
RNF213-TRAF2 interaction enhances inflammatory responses via NF-κB activation in moyamoya disease. (PubMed, Int Immunol)
In vivo, RNF213 depletion attenuated inflammation in an NF-κB-dependent imiquimod-induced ear swelling model...Collectively, these findings establish RNF213 as a pivotal regulator of NF-κB-driven inflammation and suggest that the p.R4810K variant amplifies inflammatory signaling, thereby contributing to MMD pathogenesis. This study not only advances our understanding of MMD pathophysiology but also highlights potential therapeutic strategies targeting inflammation.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
Zyclara (imiquimod)
14d
Exploring SIK2-CXCL5 interactions in neutrophils: A novel mechanism for modulating IL-23 and psoriasis progression. (PubMed, Immunol Cell Biol)
We combined in vivo and in vitro approaches to examine SIK2's role in an imiquimod (IMQ)-induced psoriasis model and activated neutrophils...In vitro, SIK2 overexpression resulted in reduced cell viability and proliferation, with corresponding reductions in IL-1β, IL-17, IL-23, and Matrix Metallopeptidase 9 levels, whereas overexpression of CXCL5 reversed these effects. Our findings suggest that SIK2 acts as a critical modulator in psoriasis by influencing CXCL5-mediated IL-23 secretion in neutrophils, underscoring the potential of SIK2 as a therapeutic target to alleviate the inflammatory responses in psoriasis.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • MMP9 (Matrix metallopeptidase 9) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • IL1B (Interleukin 1, beta)
|
Zyclara (imiquimod)
23d
Entadamide A-β-D-glucopyranoside Attenuates Psoriatic Dermatitis by Restoring Keratinocyte Homeostasis and Suppressing Neutrophil Extracellular Traps. (PubMed, J Ethnopharmacol)
EA alleviates psoriasiform dermatitis by restoring keratinocyte homeostasis, suppressing immune cell infiltration and NET formation, suggesting its potential as a therapeutic agent derived from TCM.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMGB1 (High Mobility Group Box 1) • KRT17 (Keratin 17) • PCNA (Proliferating cell nuclear antigen) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • KRT16 (Keratin 16)
|
Zyclara (imiquimod)
25d
TLR7 Agonist Imiquimod Improves the Therapeutic Antitumor Effect of High-Dose-Rate Brachytherapy. (PubMed, Cancers (Basel))
The combination of IMQ with HDR brachytherapy induces a synergistic effect, improving the therapeutic antitumor effect of brachytherapy. Our data indicate that it is reasonable to use drugs that prevent changes in the TME in combination with radiotherapy.
Journal
|
CD8 (cluster of differentiation 8)
|
Zyclara (imiquimod)
26d
Effects of Overload on Imiquimod-Induced Psoriasis Model Mice: A Basic Experimental Study. (PubMed, Health Sci Rep)
Moreover, pathological changes induced by strenuous exercise were observed in the enthesis, including angiogenesis and upregulated expression of TNF-α and MMP-13. This study revealed that strenuous exercise exacerbates pathological changes in IMQ-induced psoriasis model mice.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha)
|
Zyclara (imiquimod)
29d
Deformable Albumin-Hitchhiking Nanocarriers Loaded in Gelatin Microspheres for Immune Cell Recruitment and Cancer Immunotherapy. (PubMed, Adv Healthc Mater)
Toward that end, we engineered BIO-GEM, a hierarchically structured biomimetic lymph node (bLN) platform comprising genipin-crosslinked gelatin microspheres (GEM) encapsulating deformable albumin-hitchhiking nanoemulsions (BIO, generated with bovine albumin, imiquimod adjuvant, and OVA antigen)...In multiple B16 murine melanoma models, BIO-GEM significantly suppressed tumor growth and extended the survival of mice. Intradermal vaccination was more efficacious than subcutaneous or intramuscular injection routes.
Journal
|
CD8 (cluster of differentiation 8)
|
Zyclara (imiquimod)
1m
Isolinderalactone targets TNF-α/STAT3 inflammatory pathways to attenuate psoriasis-like dermatitis. (PubMed, Eur J Pharmacol)
Isolinderalactone exhibits anti-inflammatory activity through multiple mechanisms, highlighting the potential of topical Isolinderalactone therapy for mild-to-moderate psoriasis.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A)
|
Zyclara (imiquimod)
1m
A Bioluminescence Reporter Mouse Strain for In Vivo Imaging of IFNγ Cell Localization and Function. (PubMed, Immunology)
The validation confirmed that this model is capable of directly detecting Poly(I:C) -induced transient IFNγ, enhancing intratumoral IFNγ signals upon anti-PD-1/CTLA-4 therapy, and dynamically tracking IFNγ expression during imiquimod-induced psoriasis. This transgenic mouse model provides a powerful tool for non-invasive, longitudinal tracking of IFNγ-expressing cells, offering novel insights into IFNγ-mediated immune regulation in inflammation and cancer. It holds promise for identifying IFNγ-related therapeutic targets and predicting responses to immunotherapies.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma)
|
Zyclara (imiquimod)